

Event: IMI impact on data, 9 June 2021

SPEAKER BIO



Lars Bullinger
Director of the Department of Haematology,
Oncology and Tumourimmunology
Charité Universitätsmedizin Berlin

Lars Bullinger holds a full professorship for “Haematology and Oncology” and is the Medical Director of the Department of Haematology, Oncology and Tumour-immunology at the Virchow Campus of the Charité University Medicine in Berlin. His work concentrates on translational research with a focus on the integrative analyses of “omics” and NGS data with the aim to further refine molecular tumour classification and to implement insights into innovative precision medicine approaches.

In addition, Lars’s work aims to further advance innovative treatment concepts for haematological malignancies such as acute myeloid leukaemia (AML) and he is coordinating the Charité Leukaemia Program.

Lars’s lab is committed to unravelling the genomic, epigenomic and transcriptomic changes leading up to and driving acute myeloid leukaemia (AML) and other haematological malignancies. To this end, they employ massively parallelized next-generation sequencing (NGS) technologies, from Illumina and Oxford nanopore, to compare patient-derived primary tumour and matched control samples. Data analysis is developed and performed in-house by their own small team of bioinformaticians; findings of interest are followed up by functional validation in the lab. With close ties to the clinic, they are thus able to connect bench and bedside with their research in a dynamic exchange between dry in-silico and hands-on wet lab work.

Lars’s team are also well connected internationally and, for example, heavily involved in large cooperative projects such as SYNtherapy, Meet-AML, HARMONY and HARMONYplus.